SCHEMBL5094541

SCHEMBL5094541

COc1cc2c(cc1OC)C(Cc1ccc(-c3ccc(F)cc3OC)cc1)N(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C19 P33261 1/20 0.59
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
POLB P06746 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TP53 P04637 3/20 0.47
LMNA P02545 2/20 0.47
TRPV1 Q8NER1 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5090978 0.86 CYP3A4 (0.64) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL3541010 0.86 CYP3A4 (0.64) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL4344459 0.85 CYP2D6 (0.58) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL25142601 0.85 CYP2D6 (0.67) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL4489157 0.85 CYP2D6 (0.62) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL4345347 0.84 CYP2D6 (0.58) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL3546897 0.84 CYP2D6 (0.67) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL5103507 0.84 GRIN2C (0.60) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL4511673 0.84 CYP2D6 (0.61) CYP3A4CYP2D6CYP2C19MEN1KMT2A
SCHEMBL21346704 0.83 CYP2D6 (0.65) CYP3A4CYP2D6CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy MILLER DUANE D 2008-02-07 US disclosed
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy MILLER DUANE D 2008-02-07 US disclosed
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy MILLER DUANE D 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy BAD, TP53, MCL1 CYP3A4 4114/4885CYP2D6 4453/4885CYP2C19 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.